IN-VIVO PHARMACOKINETIC STUDIES OF SULFASALAZINE SOLID LIPID NANOPARTICLES

Abstract

Nanoparticles, particularly Solid Lipid Nanoparticles (SLNs), are increasingly utilized as efficient drug delivery systems due to their ability to enhance bioavailability, provide controlled release, and improve drug stability. SLNs offer significant advantages over traditional drug delivery systems, especially in targeting specific sites, such as the colon, for drugs like sulfasalazine used in the treatment of inflammatory bowel diseases. Sulfasalazine, although effective, suffers from poor solubility and variable bioavailability, limiting its therapeutic potential. In this study, sulfasalazine-loaded SLNs were developed and their in vivo pharmacokinetics were evaluated using a randomized animal model. The pharmacokinetic parameters, including absorption (Tmax), maximum plasma concentration (Cmax), elimination half-life (t1/2), and systemic exposure (AUC), were compared between the SLN formulation and pure sulfasalazine. The results demonstrated that SLNs significantly improved the absorption and bioavailability of sulfasalazine, with a higher Cmax and prolonged drug retention compared to the pure drug. The SLN formulation showed a more stable and sustained release profile, suggesting potential advantages in reducing dosing frequency and improving therapeutic efficacy. These findings indicate that sulfasalazine-loaded SLNs offer a promising alternative to conventional formulations, enhancing the drug’s bioavailability and effectiveness in the treatment of gastrointestinal disorders.